close
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr;54(2):390-398.
doi: 10.1111/1475-6773.13113. Epub 2019 Jan 21.

County-level access to opioid use disorder medications in medicare Part D (2010-2015)

Affiliations

County-level access to opioid use disorder medications in medicare Part D (2010-2015)

Amanda J Abraham et al. Health Serv Res. 2019 Apr.

Abstract

Objective: To identify geographic disparities in access to opioid use disorder (OUD) treatment medications and county demographic and economic characteristics associated with access to buprenorphine and oral naltrexone prescribers in Medicare Part D.

Data sources/study setting: We utilized data from the Medicare Part D Prescription Drug Event Standard Analytic File (2010-2015).

Study design/data collection: We used logistic regression to examine county-level access to OUD medication prescribers.

Principal findings: There was a 5.6 percentage point increase in counties with access to an OUD prescriber over the study period. However, in 2015, 60 percent of US counties lacked access to a Medicare Part D buprenorphine prescriber and over 75 percent lacked access to an oral naltrexone prescriber. Increased access to OUD prescribers was largely concentrated in urban counties. Results of logistic regression indicate regional differences and potential racial disparities in access to OUD prescribers.

Conclusions: To improve access to buprenorphine and naltrexone treatment for Medicare Part D enrollees, CMS may consider implementing educational and training initiatives focused on OUD treatment, offering training to obtain a buprenorphine waiver at no cost to providers, and sending targeted information to providers in low OUD treatment capacity areas.

Keywords: access; buprenorphine; medicare; naltrexone; opioid use disorder.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to report.

Figures

Figure 1
Figure 1
Number of buprenorphine prescribers per 1000 Medicare enrollees, 2010 and 2015. A, Number of buprenorphine prescribers (per 1000 enrollees) by county 2010. B, Number of buprenorphine prescribers (per 1000 enrollees) by county 2015 [Color figure can be viewed at wileyonlinelibrary.com]
Figure 2
Figure 2
Number of oral naltrexone prescribers per 1000 Medicare enrollees, 2010 and 2015. A, Number of naltrexone prescribers (per 1000 enrollees) by county 2010. B, Number of naltrexone prescribers (per 1000 enrollees) by county 2015 [Color figure can be viewed at wileyonlinelibrary.com]

References

    1. Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid‐involved overdose deaths – United States, 2010‐2015. MMWR Morb Mortal Wkly Rep. 2016;65(5051):1445‐1452. - PubMed
    1. Centers for Disease Control and Prevention . Wide‐ranging online data for epidemiologic research (WONDER). 2018; https://www.cdc.gov/drugoverdose/epidemic/index.html. Accessed May 1, 2018.
    1. Jones CM, Campopiano M, Baldwin G, McCance‐Katz E. National and state treatment need and capacity for opioid agonist medication‐assisted treatment. Am J Public Health. 2015;105(8):e55‐e63. - PMC - PubMed
    1. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication‐assisted therapies–tackling the opioid‐overdose epidemic. N Engl J Med. 2014;370(22):2063‐2066. - PubMed
    1. Substance Abuse and Mental Health Services Administration . National Survey of Substance Abuse Treatment Services. Bethesda, MD: Substance Abuse and Mental Health Services Administration; 2015.

Publication types

MeSH terms

LinkOut - more resources